BillionToOne
PublicBillionToOne is now publicly traded
The data on this page reflects BillionToOne's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series D
Jun 21, 2024
Est. Valuation at Exit
$1B
Total Funding Raised
$426.22M
Company Overview
BillionToOne is a molecular diagnostics company that develops ultrasensitive prenatal and oncology assays for precise detection of genetic disorders and tumor profiling from blood samples.
Sector
Healthcare/Wellness
Verticals
FemTech, Life Sciences, LOHAS & Wellness, Oncology
AI Layer
Non-AI
Keywords
BillionToOne Comparables
Compare BillionToOne with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Natera, Inc. | 84% | |
| Myriad Genetics | 83% | |
| Labcorp | 78% |
BillionToOne Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 21, 2024 | ||||
| Series C Extension | Dec 15, 2022 | ||||
| Debt | Dec 15, 2022 | ||||
| Series C | Mar 30, 2022 | ||||
| Series B | Jun 14, 2021 | ||||
Series A Extension | Mar 10, 2020 |
BillionToOne Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pacific 8 Ventures | Series C, Series A Extension |
| Time BioVentures | Series C, Series C Extension |
| NIH RADx | Grant |
| 500 Global | Seed |
| Neuberger Berman | Series D |
| Norwest Venture Partners | Series B, Series C, Series D, Series C Extension |
| Fark Labs | Series C |
BillionToOne Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access